XTL Biopharmaceuticals Ltd. (TLV: XTLB)

XTL Biopharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	1.07	1.4	2.09	2.97	3.63	4.46
Short-Term Investments	1.27	-	-	-	-	2.27
Trading Asset Securities	-	0.61	1.63	3.16	2.41	-
Cash & Short-Term Investments	2.34	2.01	3.72	6.13	6.04	6.73
Cash Growth	-18.67%	-46.09%	-39.27%	1.41%	-10.20%	-17.16%
Receivables	0.15	-	-	-	-	-
Prepaid Expenses	0.06	0.03	0.07	0.09	0.07	0.08
Other Current Assets	-	0.01	0.01	0.02	0.01	0.02
Total Current Assets	2.55	2.05	3.81	6.24	6.12	6.83
Property, Plant & Equipment	-	-	-	0	0	0
Other Intangible Assets	0.38	0.38	0.38	0.38	0.38	0.38
Total Assets	2.93	2.43	4.19	6.62	6.5	7.21
Accounts Payable	0.22	0	0	0	0	0
Accrued Expenses	-	0.21	0.19	0.23	0.25	0.23
Total Current Liabilities	0.22	0.21	0.19	0.23	0.25	0.23
Other Long-Term Liabilities	-	-	-	1.05	2.64	0.47
Total Liabilities	0.22	0.21	0.19	1.29	2.89	0.7
Common Stock	14.12	14.12	14.12	14.12	13.18	13.18
Additional Paid-In Capital	146.33	146.33	146.33	146.33	146.02	146.02
Retained Earnings	-157.76	-158.25	-156.47	-155.13	-155.61	-152.7
Comprehensive Income & Other	0.02	0.02	0.02	0.02	0.02	0.02
Total Common Equity	2.71	2.22	4	5.33	3.61	6.52
Shareholders' Equity	2.71	2.22	4	5.33	3.61	6.52
Total Liabilities & Equity	2.93	2.43	4.19	6.62	6.5	7.21
Net Cash (Debt)	2.34	2.01	3.72	6.13	6.04	6.73
Net Cash Growth	-18.67%	-46.09%	-39.27%	1.41%	-10.20%	-17.16%
Net Cash Per Share	0.00	0.00	0.01	0.01	0.01	0.01
Filing Date Shares Outstanding	544.91	544.91	544.91	544.91	514.21	514.21
Total Common Shares Outstanding	544.91	544.91	544.91	544.91	514.21	514.21
Working Capital	2.33	1.84	3.62	6.01	5.87	6.6
Book Value Per Share	0.00	0.00	0.01	0.01	0.01	0.01
Tangible Book Value	2.33	1.84	3.62	4.95	3.23	6.14
Tangible Book Value Per Share	0.00	0.00	0.01	0.01	0.01	0.01

Source: S&P Capital IQ. Standard template. Financial Sources.